Literature DB >> 26908437

Circulating Estrogens and Postmenopausal Ovarian Cancer Risk in the Women's Health Initiative Observational Study.

Britton Trabert1, Louise A Brinton2, Garnet L Anderson3, Ruth M Pfeiffer2, Roni T Falk2, Howard D Strickler4, Sarunas Sliesoraitis5, Lewis H Kuller6, Margery L Gass7, Barbara J Fuhrman8, Xia Xu9, Nicolas Wentzensen2.   

Abstract

BACKGROUND: Hormonal and reproductive factors contribute to the development of ovarian cancer, but few studies have examined associations between circulating estrogens and estrogen metabolites and ovarian cancer risk. We evaluated whether serum estrogens and estrogen metabolite levels are associated with ovarian cancer risk among postmenopausal women in a nested case-control study in the Women's Health Initiative (WHI) Observational Study (OS).
METHODS: We selected all 169 eligible epithelial ovarian cancer cases and 412 matched controls from women enrolled in WHI-OS who were not using menopausal hormones at baseline. Baseline levels of 15 estrogens and estrogen metabolites were measured via liquid chromatography/tandem mass spectrometry. Associations with ovarian cancer risk overall and stratified by histologic subtype (serous/nonserous) were analyzed using logistic regression. The mean time from serum collection to cancer diagnosis was 6.9 years.
RESULTS: Overall, we observed modest ovarian cancer risk associations among women with higher levels of estrone [OR (95% confidence interval) quintile (Q)5 vs. Q1: 1.54 (0.82-2.90), Ptrend = 0.05], as well as 2- and 4-methoxyestrone metabolites [2.03 (1.06-3.88), Ptrend = 0.02; 1.86 (0.98-3.56), Ptrend = 0.01, respectively]. Associations of estrogens and estrogen metabolites varied substantially by histologic subtype. Associations with serous tumors were universally null, while estrone [2.65 (1.09-6.45), Ptrend = 0.01, Pheterogeneity = 0.04], unconjugated estradiol [2.72 (1.04-7.14), Ptrend = 0.03, Pheterogeneity = 0.02] and many of the 2-, 4-, and 16-pathway metabolites were positively associated with nonserous tumors.
CONCLUSIONS: Our study provides novel molecular data showing an association of the parent estrogens and several estrogen metabolites with nonserous ovarian cancers. IMPACT: These findings further support the heterogeneous etiology of ovarian cancer. Cancer Epidemiol Biomarkers Prev; 25(4); 648-56. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26908437      PMCID： PMC4873440          DOI： 10.1158/1055-9965.EPI-15-1272-T

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN： 1055-9965            Impact factor:   4.254


  22 in total

1.  Ovarian cancer incidence trends in relation to changing patterns of menopausal hormone therapy use in the United States.

Authors:  Hannah P Yang; William F Anderson; Philip S Rosenberg; Britton Trabert; Gretchen L Gierach; Nicolas Wentzensen; Kathleen A Cronin; Mark E Sherman
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

Review 2.  Endogenous hormones and ovarian cancer: epidemiology and current hypotheses.

Authors:  Annekatrin Lukanova; Rudolf Kaaks
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-01       Impact factor: 4.254

3.  Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study.

Authors:  Hannah P Yang; Britton Trabert; Megan A Murphy; Mark E Sherman; Joshua N Sampson; Louise A Brinton; Patricia Hartge; Albert Hollenbeck; Yikyung Park; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2011-11-10       Impact factor: 7.396

4.  Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group.

Authors: 
Journal:  Control Clin Trials       Date:  1998-02

5.  Estrogen and anti-estrogen effects on the growth of human epithelial ovarian cancer in vitro.

Authors:  J D Nash; R F Ozols; J F Smyth; T C Hamilton
Journal:  Obstet Gynecol       Date:  1989-06       Impact factor: 7.661

6.  The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures.

Authors:  Robert D Langer; Emily White; Cora E Lewis; Jane M Kotchen; Susan L Hendrix; Maurizio Trevisan
Journal:  Ann Epidemiol       Date:  2003-10       Impact factor: 3.797

7.  Risk factors for epithelial ovarian cancer by histologic subtype.

Authors:  Margaret A Gates; Bernard A Rosner; Jonathan L Hecht; Shelley S Tworoger
Journal:  Am J Epidemiol       Date:  2009-11-12       Impact factor: 4.897

8.  Quantitative measurement of endogenous estrogens and estrogen metabolites in human serum by liquid chromatography-tandem mass spectrometry.

Authors:  Xia Xu; John M Roman; Haleem J Issaq; Larry K Keefer; Timothy D Veenstra; Regina G Ziegler
Journal:  Anal Chem       Date:  2007-09-12       Impact factor: 6.986

9.  Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.

Authors:  Weiva Sieh; Martin Köbel; Teri A Longacre; David D Bowtell; Anna deFazio; Marc T Goodman; Estrid Høgdall; Suha Deen; Nicolas Wentzensen; Kirsten B Moysich; James D Brenton; Blaise A Clarke; Usha Menon; C Blake Gilks; Andre Kim; Jason Madore; Sian Fereday; Joshy George; Laura Galletta; Galina Lurie; Lynne R Wilkens; Michael E Carney; Pamela J Thompson; Rayna K Matsuno; Susanne Krüger Kjær; Allan Jensen; Claus Høgdall; Kimberly R Kalli; Brooke L Fridley; Gary L Keeney; Robert A Vierkant; Julie M Cunningham; Louise A Brinton; Hannah P Yang; Mark E Sherman; Montserrat García-Closas; Jolanta Lissowska; Kunle Odunsi; Carl Morrison; Shashikant Lele; Wiam Bshara; Lara Sucheston; Mercedes Jimenez-Linan; Kristy Driver; Jennifer Alsop; Marie Mack; Valerie McGuire; Joseph H Rothstein; Barry P Rosen; Marcus Q Bernardini; Helen Mackay; Amit Oza; Eva L Wozniak; Elizabeth Benjamin; Aleksandra Gentry-Maharaj; Simon A Gayther; Anna V Tinker; Leah M Prentice; Christine Chow; Michael S Anglesio; Sharon E Johnatty; Georgia Chenevix-Trench; Alice S Whittemore; Paul D P Pharoah; Ellen L Goode; David G Huntsman; Susan J Ramus
Journal:  Lancet Oncol       Date:  2013-07-09       Impact factor: 41.316

10.  Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study.

Authors:  B Trabert; N Wentzensen; H P Yang; M E Sherman; A Hollenbeck; K N Danforth; Y Park; L A Brinton
Journal:  Br J Cancer       Date:  2012-08-28       Impact factor: 7.640
View more
  26 in total

1.  Testosterone and Estrone Increase From the Age of 70 Years: Findings From the Sex Hormones in Older Women Study.

Authors:  Susan R Davis; Robin J Bell; Penelope J Robinson; David J Handelsman; Tom Gilbert; James Phung; Reena Desai; Jessica E Lockery; Robyn L Woods; Rory S Wolfe; Christopher M Reid; Mark R Nelson; Anne M Murray; John J McNeil
Journal:  J Clin Endocrinol Metab       Date:  2019-12-01       Impact factor: 5.958

2.  Estrone Is a Strong Predictor of Circulating Estradiol in Women Age 70 Years and Older.

Authors:  Susan R Davis; Alejandra Martinez-Garcia; Penelope J Robinson; David J Handelsman; Reena Desai; Rory Wolfe; Robin J Bell
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

3.  Androgens Are Differentially Associated with Ovarian Cancer Subtypes in the Ovarian Cancer Cohort Consortium.

Authors:  Jennifer Ose; Elizabeth M Poole; Helena Schock; Matti Lehtinen; Alan A Arslan; Anne Zeleniuch-Jacquotte; Kala Visvanathan; Kathy Helzlsouer; Julie E Buring; I-Min Lee; Anne Tjønneland; Laure Dossus; Antonia Trichopoulou; Giovanna Masala; N Charlotte Onland-Moret; Elisabete Weiderpass; Eric J Duell; Annika Idahl; Ruth C Travis; Sabina Rinaldi; Melissa A Merritt; Britton Trabert; Nicolas Wentzensen; Shelley S Tworoger; Rudolf Kaaks; Renée T Fortner
Journal:  Cancer Res       Date:  2017-04-05       Impact factor: 12.701

4.  Association of Endogenous Pregnenolone, Progesterone, and Related Metabolites with Risk of Endometrial and Ovarian Cancers in Postmenopausal Women: The B∼FIT Cohort.

Authors:  Louise A Brinton; Cher M Dallal; Britton Trabert; Ashley M Geczik; Doug C Bauer; Diana S M Buist; Jane A Cauley; Roni T Falk; Gretchen L Gierach; Trisha F Hue; James V Lacey; Andrea Z LaCroix; Kara A Michels; Jeffrey A Tice; Xia Xu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-08-31       Impact factor: 4.090

5.  Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Women's Health Initiative Observational Study.

Authors:  Britton Trabert; Sally B Coburn; Roni T Falk; JoAnn E Manson; Louise A Brinton; Margery L Gass; Lewis H Kuller; Thomas E Rohan; Ruth M Pfeiffer; Lihong Qi; Marcia L Stefanick; Nicolas Wentzensen; Garnet L Anderson; Xia Xu
Journal:  Cancer Causes Control       Date:  2019-09-21       Impact factor: 2.506

6.  Estrogen metabolism in menopausal hormone users in the women's health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone?

Authors:  Roni T Falk; JoAnn E Manson; Vanessa M Barnabei; Garnet L Anderson; Louise A Brinton; Thomas E Rohan; Jane A Cauley; Chu Chen; Sally B Coburn; Ruth M Pfeiffer; Kerryn W Reding; Gloria E Sarto; Nicolas Wentzensen; Rowan T Chlebowski; Xia Xu; Britton Trabert
Journal:  Int J Cancer       Date:  2018-11-01       Impact factor: 7.396

7.  Postmenopausal Androgen Metabolism and Endometrial Cancer Risk in the Women's Health Initiative Observational Study.

Authors:  Kara A Michels; Louise A Brinton; Nicolas Wentzensen; Kathy Pan; Chu Chen; Garnet L Anderson; Ruth M Pfeiffer; Xia Xu; Thomas E Rohan; Britton Trabert
Journal:  JNCI Cancer Spectr       Date:  2019-04-25

8.  The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3).

Authors:  Britton Trabert; Shelley S Tworoger; Katie M O'Brien; Mary K Townsend; Renée T Fortner; Edwin S Iversen; Patricia Hartge; Emily White; Pilar Amiano; Alan A Arslan; Leslie Bernstein; Louise A Brinton; Julie E Buring; Laure Dossus; Gary E Fraser; Mia M Gaudet; Graham G Giles; Inger T Gram; Holly R Harris; Judith Hoffman Bolton; Annika Idahl; Michael E Jones; Rudolf Kaaks; Victoria A Kirsh; Synnove F Knutsen; Marina Kvaskoff; James V Lacey; I-Min Lee; Roger L Milne; N Charlotte Onland-Moret; Kim Overvad; Alpa V Patel; Ulrike Peters; Jenny N Poynter; Elio Riboli; Kim Robien; Thomas E Rohan; Dale P Sandler; Catherine Schairer; Leo J Schouten; Veronica W Setiawan; Anthony J Swerdlow; Ruth C Travis; Antonia Trichopoulou; Piet A van den Brandt; Kala Visvanathan; Lynne R Wilkens; Alicja Wolk; Anne Zeleniuch-Jacquotte; Nicolas Wentzensen
Journal:  Cancer Res       Date:  2020-01-13       Impact factor: 12.701

9.  Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium.

Authors:  Nicolas Wentzensen; Elizabeth M Poole; Britton Trabert; Emily White; Alan A Arslan; Alpa V Patel; V Wendy Setiawan; Kala Visvanathan; Elisabete Weiderpass; Hans-Olov Adami; Amanda Black; Leslie Bernstein; Louise A Brinton; Julie Buring; Lesley M Butler; Saioa Chamosa; Tess V Clendenen; Laure Dossus; Renee Fortner; Susan M Gapstur; Mia M Gaudet; Inger T Gram; Patricia Hartge; Judith Hoffman-Bolton; Annika Idahl; Michael Jones; Rudolf Kaaks; Victoria Kirsh; Woon-Puay Koh; James V Lacey; I-Min Lee; Eva Lundin; Melissa A Merritt; N Charlotte Onland-Moret; Ulrike Peters; Jenny N Poynter; Sabina Rinaldi; Kim Robien; Thomas Rohan; Dale P Sandler; Catherine Schairer; Leo J Schouten; Louise K Sjöholm; Sabina Sieri; Anthony Swerdlow; Anna Tjonneland; Ruth Travis; Antonia Trichopoulou; Piet A van den Brandt; Lynne Wilkens; Alicja Wolk; Hannah P Yang; Anne Zeleniuch-Jacquotte; Shelley S Tworoger
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

10.  Ovarian Cancer Risk Factor Associations by Primary Anatomic Site: The Ovarian Cancer Cohort Consortium.

Authors:  Shelley S Tworoger; Leo J Schouten; Renée T Fortner; Megan S Rice; Synnove F Knutsen; Michael J Orlich; Kala Visvanathan; Alpa V Patel; Mia M Gaudet; Anne Tjønneland; Marina Kvaskoff; Rudolf Kaaks; Antonia Trichopolou; Valeria Pala; N Charlotte Onland-Moret; Inger T Gram; Pilar Amiano; Annika Idahl; Naomi E Allen; Elisabete Weiderpass; Jenny N Poynter; Kim Robien; Graham G Giles; Roger L Milne; Veronica W Setiawan; Melissa A Merritt; Piet A van den Brandt; Anne Zeleniuch-Jacquotte; Alan A Arslan; Katie M O'Brien; Dale P Sandler; Alicja Wolk; Niclas Håkansson; Holly R Harris; Britton Trabert; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-07-30       Impact factor: 4.254
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.